Wang J, Wei HJ, Mao RF, Chang X. Gut microbiota modulating therapy for diabetes mellitus should be individualized. World J Diabetes 2024; 15(10): 2152-2156 [PMID: 39493555 DOI: 10.4239/wjd.v15.i10.2152]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Oct 15, 2024; 15(10): 2152-2156 Published online Oct 15, 2024. doi: 10.4239/wjd.v15.i10.2152
Gut microbiota modulating therapy for diabetes mellitus should be individualized
Jin Wang, Hong-Juan Wei, Rui-Feng Mao, Xin Chang
Jin Wang, Xin Chang, Department of Ultrasound Medicine, Nanjing Lishui People’s Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing 211200, Jiangsu Province, China
Hong-Juan Wei, Neonatal Intensive Care Unit, Nanjing Lishui People’s Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing 211200, Jiangsu Province, China
Rui-Feng Mao, School of Life Science, Huaiyin Normal University, Huai'an 223300, Jiangsu Province, China
Co-first authors: Jin Wang and Hong-Juan Wei.
Author contributions: Wang J and Wei HJ conceptualized and drafted the manuscript; Mao RF edited the manuscript; Chang X did further revisions and editorial corrections before submission. All authors have read and agreed to the published version of this manuscript. Wang J and Wei HJ contributed equally to this work as co-first authors.
Supported byMedical Education Collaborative Innovation Fund of Jiangsu University, No. JDYY2023101.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Received: July 11, 2024 Revised: September 14, 2024 Accepted: September 18, 2024 Published online: October 15, 2024 Processing time: 77 Days and 0.4 Hours
Abstract
In this editorial, we commented on two articles published online in August and September 2024 in the World Journal of Diabetes, which focused on modifying the gut microbiota (GM) to prevent or delay the progression of diabetes mellitus (DM) and DM-related complications. Numerous studies, many of which are animal studies, have indicated the potential role of GM in the pathogenesis of DM. However, the detailed causality and mechanisms between GM and DM have not been fully clarified. Although there have been some reports of a potential role of modifying the GM in treating DM, most lack long-term observations and are not mechanistic. Additionally, the GM and its role in DM might vary among individuals; therefore, GM-targeted interventions should be individualized to realize their therapeutic potential.
Core Tip: This editorial focuses on the research progress regarding the gut microbiota (GM) in the development of diabetes mellitus (DM). Revealing and understanding the precise causality and mechanisms between the GM and DM may facilitate investigations focused on modifying the GM to ameliorate DM and its complications. Additionally, as a result of the considerable interindividual heterogeneity in the GM, more precise and personalized GM-targeting therapeutic interventions should be considered.
